一个多omics R-loop-linked 风险计划强调了CKS2-阳性增殖性瘤细胞作为质瘤生长的驱动因素
Weichun Tang1, Shangshang Hu2, Xu Tong3
1The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University, Bengbu 233000, Anhui, China; Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University,Bengbu 233030, Anhui, China.
基于R循环活动的新型质瘤风险特征准确预测患者的存活率和免疫治疗反应. 这种特征突出显示了MYBL2-CKS2通路是脑瘤的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- R环,三链核酸结构,涉及到各种细胞过程和疾病.
- 在癌症中观察到异常的R环积累,但其在质瘤进展和治疗反应中的作用仍然不完全理解.
研究的目的:
- 从R-循环关联的转录程序中开发出可概括的质瘤风险特征.
- 为了评估这个签名的预后和免疫疗法预测效用.
- 定义R-循环签名的细胞和调节决定因素.
主要方法:
- 使用单样样本基因组丰富分析 (ssGSEA) 量化R循环活动.
- 大量多组质瘤群体的共识聚类,以定义亚型.
- 使用TCGA,CGGA和GEO数据集开发和验证预测模型.
- 综合性多组学分析,单细胞和空间转录组学以确定驱动因素和治疗点.
主要成果:
- 质瘤中R环活性升高与更高的WHO等级和更差的存活率相关.
- 一个R-循环高的亚型表现出最糟糕的预后和免疫逃避特征.
- 开发的风险评分强有力的分层生存率,预测较低的免疫疗法益处,和优于现有的质瘤签名.
- 高风险项目主要位于增殖性瘤细胞状态,其中CKS2被确定为关键驱动因素.
- 确定了MYBL2-CKS2轴作为一个关键的调节途径,GSK269962A显示了目标有效性.
结论:
- 一个R-循环定风险签名为质瘤患者提供了强大的预后和免疫疗法分层.
- MYBL2-CKS2轴代表了一个显著的漏洞和潜在的翻译目标,用于质瘤治疗.
更多相关视频
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Cancers Originate from Somatic Mutations in a Single Cell
